News Article

UTMB scientists awarded $11.3 million for new studies on Ebola virus

May 17, 2021 • 6:03 a.m.

Researchers at the University of Texas Medical Branch at Galveston have been awarded an $11.3 Million, multi-year grant from the National Institute of Allergy and Infectious Diseases to study immunopathogenesis of Ebola, and in particular to determine why cells infected with Ebola develop “immune system paralysis,” which inhibits immune response leads to hyper inflammation and allows the deadly infection to spread. The research will be led by Co-Principal Investigators Alexander Bukreyev, PhD., of UTMB’s Department of Pathology, and Mariano Garcia-Blanco, MD, PhD, Chair of the Biochemistry and Molecular Biology Department.

New study looks at long-term outcomes and costs of high-risk non-muscle invasive bladder cancer treatment

March 31, 2021 • 11:00 a.m.

A new research study leveraging a database from the largest equal access health system in the US, the Department of Veteran Affairs offers insight into the outcome of specific treatment patterns for advanced bladder cancer patients. Lead author Dr. Stephen Williams of the University of Texas Medical Branch says it is one of the first comprehensive studies looking at both the outcomes and the costs of treating a potentially lethal and devastating type of bladder cancer.

Combination Therapy Protects Against Advanced Marburg Virus Disease

March 26, 2021 • 11:21 a.m.

A new study conducted at the Galveston National Laboratory at The University of Texas Medical Branch at Galveston (UTMB) has shown substantial benefit to combining monoclonal antibodies and the antiviral remdesivir against advanced Marburg virus. The study was published today in Nature Communications.

All encouraged to sign-up for COVID vaccine waitlist as state expands eligibility

March 23, 2021 • 11:00 a.m.

The Galveston County vaccination partnership is encouraging anyone 16 and older, regardless of medical conditions, to sign up for the Galveston County COVID-19 vaccine waitlist.

UTMB part of network to help students develop entrepreneurship skills

March 12, 2021 • 9:00 a.m.

The University of Texas Medical Branch now is a part of a global network that promotes student entrepreneurship, training, and mentoring with academic and industry professionals.

Researchers at UTMB find that frustration is an additional factor of addiction based on studies with rats

March 2, 2021 • 9:00 a.m.

A team from The University of Texas Medical Branch at Galveston (UTMB) focused on drug addiction research have pioneered a new way to study frustration as a factor in substance use disorders. The study was published in the medical journal Psychopharmacology.

UTMB and Pfizer scientists release further studies of U.K. and South African variants of COVID-19

February 9, 2021 • 10:22 a.m.

A collaborative team from The University of Texas Medical Branch at Galveston (UTMB) and Pfizer has shown that the common mutations of SARS-CoV-2 that have appeared in the United Kingdom and South Africa strains of the virus can be neutralized by the Pfizer COVID-19 vaccine.

UTMB Team Proves Potential for Reducing Pre-Term Birth by Treating Fetus as Patient

January 27, 2021 • 2:00 p.m.

The results of a study by researchers at the University of Texas Medical Branch may pave the way for a new medicine delivery system that could reduce the incidence of pre-term labor and premature birth by allowing physicians to treat the ‘fetus as the patient’. The study has been published in Science Advances.

Breast milk can be powerful, but can it stop the new coronavirus?

January 19, 2021 • 8:00 a.m.

There is a lot we do not know about SARS-CoV-2, the virus that causes COVID-19, including how it may interact with human milk. However, researchers at the University of Texas Medical Branch are trying to figure out if breast milk has any innate ability to stop the spread of the virus that causes COVID-19, or if an infected mother can pass antibodies to her breastfeeding child.

UTMB researchers find Pfizer vaccine effective against new COVID-19 strain

January 8, 2021 • 11:00 a.m.

A collaborative team from The University of Texas Medical Branch at Galveston and Pfizer has shown that the common mutation N501Y from the newly emerged SRAS-CoV-2 strains does not compromise Pfizer’s COVID-19 vaccine. This is the first study to investigate if the fast-spreading new virus strains affects the vaccine’s effectiveness. The study is currently available in bioRxiv (https://doi.org/10.1101/2021.01.07.425740).

Categories